This ADC product is comprised of an anti-PTK7 monoclonal antibody conjugated via a linker to auristatin. The auristatin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, auristatin binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
ADC Target
- Alternative Names
- PTK7; protein tyrosine kinase 7 (inactive); CCK4; CCK-4; inactive tyrosine-protein kinase 7; colon carcinoma kinase 4; PTK7 protein tyrosine kinase 7; tyrosine-protein kinase-like 7; pseudo tyrosine kinase receptor 7;
- Target Entrez Gene ID
- 5754
- Overview
- This gene encodes a member of the receptor protein tyrosine kinase family of proteins that transduce extracellular signals across the cell membrane. The encoded protein lacks detectable catalytic tyrosine kinase activity, is involved in the Wnt signaling pathway and plays a role in multiple cellular processes including polarity and adhesion. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
ADC Antibody
- Overview
- Anti-PTK7 Antibody
ADC Linker
- Name
- VC (valine-citrulline)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products